Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, ...

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial ...

3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

Huntsville police will implement a DUI checkpoint on July 4 to deter impaired driving and enhance safety. Authorities urge ...